Abstract 18444: Low and Exacerbated Levels Of 1,5-anhydroglucitol are Associated With Cardiovascular Events in Patients After First-time Elective Percutaneous Coronary Intervention
Background: There has recently been great interest in the association between postprandial hyperglycemia and coronary artery disease. Serum 1,5-anhydroglucitol (1,5-AG) is reported to be a clinical marker of postprandial hyperglycemia. However, the impact of 1,5-AG on cardiovascular events has not been fully investigated.
Methods: We enrolled 270 consecutive patients who had undergone first-time elective percutaneous coronary intervention (PCI) with follow-up angiography within 1 year. Fasting blood glucose (FBS) levels, HbA1c, and 1,5-AG were measured prior to PCI and at the time of follow-up angiography. Clinical events, including ACS and coronary revascularization, were also evaluated. Subjects were divided into two groups according to clinical outcomes: event group (EV, n=48) and non-event group (NEV, n=222). Patients were also divided into four groups according to 1,5-AG levels prior to PCI and at follow-up: increased 1,5-AG group (Group A), persistently low 1,5-AG group (Group B), persistently high 1,5-AG group (Group C) and decreased 1,5-AG group (Group D).
Results: No significant differences in baseline clinical characteristics were observed between the two or the four 1,5-AG groups. Serum levels of 1,5-AG at follow-up were significantly lower in the EV group than in the NEV group (P=0.04). Significant reduction in 1,5-AG level was observed in the EV group than in the NEV group (P = 0.03). The association between 1,5-AG levels and clinical events remained significant after adjustment for independent variables, including FBS and HbA1c levels (P=0.04). The incidence of cardiovascular events was significantly higher in Group D than the other 1,5-AG groups. (Figure)
Conclusion: Low and exacerbated levels of 1,5-AG were associated with cardiovascular events, suggesting that postprandial hyperglycemia and low 1,5-AG are important risk factors for adverse clinical events in patients after first-time elective PCI.
Author Disclosures: S. Takahashi: None. K. Shimada: None. K. Miyauchi: None. E. Sai: None. T. Miyazaki: None. T. Shiozawa: None. H. Tamura: None. S. Okazaki: None. K. Isoda: None. H. Daida: None.
- © 2015 by American Heart Association, Inc.